
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics, Inc. is gaining traction in the pharmaceutical sector with its focus on developing innovative treatments for cancer, particularly through its lead candidate, rhenium (186Re) obisbemeda, which is under investigation for central nervous system cancers. The FDA's encouragement regarding an accelerated approval pathway for Reyobiq in treating leptomeningeal metastases highlights the significant unmet medical need in this area and suggests the potential for therapeutic success. Additionally, the company's recent public offering that raised approximately $15 million enhances its financial position, allowing for increased operational flexibility and advancement in pivotal trial preparations, thereby strengthening the outlook for Plus Therapeutics.
Bears say
The financial outlook for Plus Therapeutics Inc. is negatively impacted by a reduced price target, which has been lowered to $1.00 per diluted share from a previous target of $2.00, reflecting concerns about the company's valuation and potential market performance. Additionally, the uncertainty associated with the clinical study outcomes for its lead product, rhenium (186Re) obisbemeda, is heightened due to variability in median overall survival rates reported in prior studies, creating further challenges for investor confidence. Lastly, the recent equity offering and the anticipated exercise of associated warrants may dilute existing shareholder value, contributing to a cautious market sentiment towards the company.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares